{"nctId":"NCT01340768","briefTitle":"Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)","startDateStruct":{"date":"2010-06-22","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":870,"armGroups":[{"label":"Sitagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin","Drug: Metformin"]},{"label":"Sulfonylurea Therapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sulfonylurea","Drug: Metformin"]}],"interventions":[{"name":"Sitagliptin","otherNames":["Sitagliptin phosphate, MK-0431, JANUVIA®"]},{"name":"Sulfonylurea","otherNames":["Amaryl (glimepiride)"]},{"name":"Metformin","otherNames":["Glucophage"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Muslim, with type 2 diabetes mellitus\n* Intends to fast during the month of Ramadan\n* Hemoglobin A1c (HbA1c) ≤10% at screening\n* On a stable dose of a SU drug (glibenclamide, glimepiride, or gliclazide), for at least three months, with or without metformin therapy at a stable dose\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* Pregnant or breast feeding or with gestational diabetes\n* Hypersensitivity or contraindication to dipeptidyl peptidase-4 (DPP-4) treatment\n* Serum creatinine ≥1.5 mg/dL (males), ≥1.4 mg/dL (females)\n* History of severe hypoglycemia (defined as a hypoglycemic event requiring the assistance of another individual, and/or resulting in a emergency department admission, physician office visit and/or hospitalization)\n* Any use of insulin (prior to or during Ramadan)\n* Use of any class of oral antidiabetic therapy other than an SU or metformin\n* Current participation in another interventional study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With at Least One Symptomatic Hypoglycemic Event","description":"Symptomatic hypoglycemic events were based on the participants own self-reported symptoms (for example, but not limited to the following: faintness, headache, confusion, anxiety, sweating, tremor, palpitations, nausea, pallor, dizziness, hunger, sudden behavioral change).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"7.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event","description":"Symptomatic hypoglycemic events were based on the participants own self-reported symptoms (for example but not limited to the following: faintness, headache, confusion, anxiety, sweating, tremor, palpitations, nausea, pallor, dizziness, hunger, sudden behavioral change). Asymptomatic hypoglycemic events were based on self-monitored finger-stick blood glucose level.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null},{"groupId":"OG001","value":"9.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":421},"commonTop":["Hypoglycemia"]}}}